Filing Flows

Filing Flows › Companies › DataMeds AI › Cash flow

DataMeds AI cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.9M in Q2 2026 · −$13.7M over twelve months

Operating cash flow−$2.9M
Free cash flow−$2.9M

Analysis

In Q2 2026, DataMeds AI generated −$2.9M of operating cash flow. That is $815K less than in Q2 2025 (−$2.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$13.7M; the largest uses were operating cash flow ($13.7M), other investing ($924K), net borrowing (+) / repaid (−) ($37K); besides operations, cash came from other financing ($16.7M); the cash balance rose by $2.0M.

Operating cash flow was −$2.9M against net income of −$18.4M. The largest differences: accrued liabilities +$2.6M, stock-based pay +$1.2M, payables +$960K.

Free cash flow

DataMeds AI: free cash flow by quarterDataMeds AI: free cash flow by quarter$1.0MQ3 2024−$2.6MQ4 2024−$1.3MQ1 2025−$2.1MQ2 2025−$1.1MQ3 2025−$6.3MQ4 2025−$3.4MQ1 2026−$2.9MQ2 2026
Operating cash flow less capital spending.
DataMeds AI: operating cash flow against capital spendingDataMeds AI: operating cash flow against capital spendingOperating cash flowCapital spending$1.0M$0Q3 2024−$2.6M$0Q4 2024−$1.3M$0Q1 2025−$2.1M$0Q2 2025−$1.1M$0Q3 2025−$6.3M$0Q4 2025−$3.4M$0Q1 2026−$2.9M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.9M, Capital spending $0.

Capital allocation, year by year

DataMeds AI: where the cash came from (up) and went (down), by fiscal yearDataMeds AI: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2023: Operating cash flow −$349KFY2023: Net borrowing $350K$350KFY2023FY2024: Operating cash flow −$1.2MFY2024: Net borrowing $1.4MFY2024: Shares issued $10K$1.4MFY2024FY2025: Operating cash flow −$10.9MFY2025: Net borrowing $21.9MFY2025: Shares issued $4.0M$25.9MFY2025
Over these 3 years operating cash flow totalled −$12.4M; the largest uses were operating cash flow ($12.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.5M
Debt$31.8M
Net debt$29.3M
Due within a year$10.9M
Cash runway2 months

DataMeds AI is burning cash: its operations consume cash, a free cash flow of −$13.7M a year at the current rate against $2.5M of cash and investments: a runway of about 2 months; $10.9M of debt also comes due within a year, which would need refinancing or new money before any new financing.

DataMeds AI: debt maturities by year (FY2025)DataMeds AI: debt maturities by year (FY2025)$10.9MYear 1$5.1MYear 2$7.5MYear 3
Principal due in each year as disclosed in the annual report, against $2.5M of cash and investments now.

Where the cash came from and went

DataMeds AI: sources (+) and uses (−) of cash, Q2 2026DataMeds AI: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)$8.2MOperating cash flow−$2.9MOther financing−$2.7MCash drawn (+) / kept (−)−$2.4MOther investing−$242K
DataMeds AI: sources (+) and uses (−) of cash, TTM to Q2 2026DataMeds AI: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$16.7MOperating cash flow−$13.7MCash drawn (+) / kept (−)−$2.0MOther investing−$924KNet borrowing (+) / repaid (−)−$37K

From profit to cash

DataMeds AI: net income to operating cash flow, Q2 2026DataMeds AI: net income to operating cash flow, Q2 2026Net income−$18.4MDepreciation & amortization$357KStock-based pay$1.2MReceivables−$302KInventory$131KPayables$960KAccrued liabilities$2.6MOperating cash flow−$2.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.9M$8.2M—−$2.4M−$2.9M
Q1 2026−$3.4M$3.9M—−$9K−$3.4M
Q4 2025−$6.3M$1.1M—$4.2M−$6.3M
Q3 2025−$1.1M$3.2M—−$3.8M−$1.1M
Q2 2025−$2.1M——$2.1M−$2.1M
Q1 2025−$1.3M−$75K$4.0M−$1.5M−$1.3M
Q4 2024−$2.6M——−$235K−$2.6M
Q3 2024$1.0M——−$726K$1.0M

DataMeds AI: income statement and cash flow

DataMeds AI, Q2 2026: revenue $1.8M (-77% year over year), operating margin -412.7%. The chart follows the revenue to costs, profit and cash.

DataMeds AI: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.